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Background: Evidence for the use of telephone consultation in childhood inﬂammatory bowel disease (IBD) is
lacking. We aimed to assess the effectiveness and cost consequences of telephone consultation compared with
the usual out-patient face-to-face consultation for young people with IBD.
Methods:We conducted a randomised-controlled trial in Manchester, UK, between July 12, 2010 and June 30,
2013. Young people (aged 8–16 years) with IBD were randomized to receive telephone consultation or face-
to-face consultation for 24 months. The primary outcome measure was the paediatric IBD-speciﬁc IMPACT
quality of life (QOL) score at 12 months. Secondary outcomemeasures included patient satisfaction with consul-
tations, disease course, anthropometricmeasures, proportion of consultations attended, duration of consultations,
and costs to the UK National Health Service (NHS). Analysis was by intention to treat. This trial is registered with
ClinicalTrials.gov, number NCT02319798.
Findings: Eighty six patientswere randomised to receive either telephone consultation (n=44) or face-to-face con-
sultation (n = 42). Baseline characteristics of the two groups were well balanced. At 12 months, there was no
evidence of difference in QOL scores (estimated treatment effect in favour of the telephone consultation group
was 5.7 points, 95% CI−2.9 to 14.3; p=0.19). Mean consultation timeswere 9.8min (IQR 8 to 12.3) for telephone
consultation, and 14.3 min (11.6 to 17.0) for face-to-face consultation with an estimated reduction (95% CI) of
4.3 (2.8 to 5.7) min in consultation times (p b 0.001). Telephone consultation had amean cost of UK£35.41 per pa-
tient consultation comparedwith £51.12 for face-face consultation, difference £15.71 (95% CI 11.8–19.6; P b 0.001).
Interpretation:We found no suggestion of inferiority of telephone consultation compared with face-to-face consul-
tationwith regard to improvements in QOL scores, and telephone consultation reduced consultation time and NHS
costs. Telephone consultation is a cost-effective alternative to face-to-face consultation for the routine outpatient
follow-up of children and adolescents with IBD.
Funding: Research for Patient Beneﬁt Programme, UK National Institute for Health Research.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Crohn's disease and ulcerative colitis, collectively known as inﬂam-
matory bowel disease (IBD) are chronic relapsing disorders of the gas-
trointestinal tract. The incidence of childhood IBD has been increasing
in theUK (Cosgrove et al., 1996; Gunesh et al., 2008) and is currently es-
timated to be 5.2 per 100,000 per year in people younger than 16 yearstric Gastroenterology, Royal
, M13 9WL, UK.
kobeng).
. This is an open access article underold (Sawczenko et al., 2001). There is no medical cure for IBD and the
natural history of the disorder is characterised by recurrent relapses
alternating with periods of remission. In between periods of ill health,
patients can be well for prolonged periods of time when their disease
is in remission. At routine outpatient hospital reviews, patients are
often well and do not usually require any intervention, highlighting
the fact that regular ﬁxed appointments do not necessarily coincide
with disease relapses (Gethins et al., 2007).
In the UK, children with IBD are usually managed by paediatric gas-
troenterologists who are based in a few regional centres. Conventional-
ly, patients are kept under routine face-to face outpatient follow-up.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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together with their families, have to travel long distances in order to at-
tend out-patient clinics. For children who are doing well, such routine
visits may be unnecessary.
Telephone consultations allow patients to have contact with
healthcare professionals without the patient having to travel. For pa-
tients, the beneﬁts of telephone consultations may include reduced
travel time, reduced costs, and improved satisfaction (Car and Sheikh,
2003). In adults with various chronic diseases, telephone consultations
were associated with reducedmedical care utilisation without adverse-
ly affecting patient health (Wasson et al., 1992). Telephone consulta-
tions also cost-effectively increased asthma review rates, enhancing
patient conﬁdence with management, with no detriment to asthma
morbidity (Pinnock et al., 2007). No study comparing telephone consul-
tations with face-to-face consultations for children with IBD has been
reported, but at least two uncontrolled studies have been reported
in adults with IBD (Gethins et al., 2007; Miller et al., 2002). Miller
et al. showed that a telephone clinic improved the overall quality of
follow-up care for adults with IBD (Miller et al., 2002). In another
study, Gethins et al. found that telephone clinics signiﬁcantly reduced
non-attendance rates and waiting times for urgent appointments
(Gethins et al., 2007). Despite the potential advantages of telephone
consultations, this approach has been given little attention in young
people with IBD. We, therefore, aimed to provide evidence about the
effectiveness and cost consequences of telephone consultations, com-
pared to face-to-face consultations in childhood IBD.2. Methods
2.1. Setting and Participants
Weconducted a randomised-controlled trial at theRoyalManchester
Children's Hospital, Manchester, UK, a regional Paediatric Gastroenterol-
ogy referral centre. Children and adolescents with IBD from the North
West of England are referred to this centre. Any patient who was aged
between 8 and 16 years with a diagnosis of IBD was eligible for entry
into the trial.
We identiﬁed eligible patients through the hospital's paediatric IBD
database. Inclusion criteria were: diagnosis of IBD by established clini-
cal, endoscopic, histological and radiological criteria; clinical remission
deﬁned as an abbreviated Paediatric Crohn's Disease Activity Index
(aPCDAI) score of ≤10 (Shepanski et al., 2004) for patients with Crohn's
disease or as a Paediatric Ulcerative Colitis Activity Index (PUCAI) score
of b10 (Turner et al., 2007) for thosewith ulcerative colitis and indeter-
minate colitis. Exclusion criteria were: active disease (aPCDAI N15 or
PUCAI ≥15), and unwillingness to provide informed consent.
We sent a letter of invitation to participate in the study and a research
information sheet outlining the nature of the study to eligible pa-
tients and their parents. Those who agreed to take part were
interviewed by an investigator who provided full information
about the trial and obtained parental and child's written informed
consent. We obtained ethics approval from the North West of England
research ethics committee.2.2. Randomization and Masking
By means of a computer-generated randomisation scheme, partici-
pants were allocated to telephone consultation or face-to-face consulta-
tion. We used randomization with blocks of random sizes, and stratiﬁed
by type of disease (i.e. Crohn's disease or ulcerative colitis/indeterminate
colitis). The assignment schedule was held centrally and allocation was
performed by staff of the hospital's pharmacy department independent
from the trial team. Masking was not possible because of the nature of
the two interventions.2.3. Procedures
Patients in both groups were offered out-patient appointment dates
and times. Those randomized to face-to-face consultation were asked
to attend their routine appointments in hospital as usual. Those
randomised to telephone consultation were told to expect a call from
the gastroenterology doctor at the time of their appointment. The
consulting doctor contacted the patient and parents via a telephone
number (home or mobile) that the parents and patient had previously
supplied as the number they would like to be contacted on. As much
as possible, parents and patients were advised to be together at the
time of the appointment in order to allow both of them to participate
in the consultation as is usual in practice. Up to three attempts within
20 min were made to contact patients by phone. Patients who did not
attend an appointment in either group were sent another appointment
in accordance with our hospital's policy.
Apart from being randomised to telephone or face-to-face consulta-
tion, routine care was the same for patients in both groups. As it is in
normal practice, if a participant experienced any symptoms that caused
concern at any time during the study, the parent/child contacted the IBD
nurse for advice and appropriate arrangements for assessment were
made.
2.4. Outcomes
The primary outcome was quality of life (QOL) score at 12 months.
QOL scores were assessed using the validated paediatric IBD IMPACT
QOL questionnaire (Otley et al., 2002; Loonen et al., 2002; Ogden
et al., 2011). Secondary outcomemeasureswere patient and parent sat-
isfactionwith consultations (assessedwith the Consultation Satisfaction
Questionnaire {CSQ}) (Baker, 1990); the number of disease relapses
(relapse deﬁned by the aPCDAI or PUCAI); anthropometric measures
(body mass index (BMI), height, and weight z-scores); number of
hospital admissions; proportion of consultations attended; duration of
consultations (measured with a watch); and costs to the UK National
Health Service (NHS).
2.5. Statistical Analysis
Our sample size was based on the primary outcome measure and
drew on previous studies (Shepanski et al., 2005; Afzal et al., 2004),
where the minimum clinically important change in QOL scores was de-
termined to be 10 points (total QOL scores range from 0 to 140 with
higher scores representing better QOL). A power calculation indicated
the need for 74 participants (37 participants per arm) to have at least
80% power at the 5% signiﬁcance level to detect a 10 point difference
in QOL scores at 12 months.
All data were analysed on an intention-to-treat (ITT) basis. For
the primary and secondary quantitative/summary score outcomes
(QOL score, anthropometric measures, CSQ scores and duration of con-
sultations) analysis of covariance was used. For secondary count out-
comes (number of disease relapses and number of hospital admissions
for IBD), Poisson regression models were used. For the proportion
of out-patient consultations attended throughout the duration of the
study, a binomial logistic model was ﬁtted. For all models, the baseline
outcome in question, and disease type were included as covariates.
The mean difference, the rate ratio, and the odds ratio on the treatment
allocation factor were estimated as appropriate to evaluate the inter-
vention effect. All tests were conducted at a signiﬁcance level of 5%.
Missing baseline data were imputed as a ‘missing’ category for dis-
crete covariates or using simple conditional mean imputation (White
and Thompson, 2005) for continuous covariates. Sensitivity analyses
for the primary outcome included multiple imputation under a pattern
mixture model (Little, 1993) to explore informatively missing outcome
data. This involved performing standard multiple imputation on the
QOL data but modelling a conditional difference (delta) between these
Fig. 1. Trial proﬁle. IMPACT = Paediatric IBD quality of life questionnaire.
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Table 1
Baseline characteristics.
Characteristic Control
“face-to-face”
Intervention
“telephone”
Disease type
Crohn's disease (%) 35
(83)
36
(82)
Ulcerative or indeterminate colitis (%) 7
(17)
8
(18)
Gender
Male (%) 24
(57)
30
(68)
Female (%) 18
(43)
14
(32)
Age, years 13.8
(11.2, 15.3)
13.9
(12.1, 15.9)
IMPACT QOL score 110
(96, 121)
[1]
112
(100, 120)
[1]
BMI, kg/m2 20.2
(17.2, 22.1)
[1]
20.1
(18.2, 23.1)
[0]
Weight, kg 48.5
(37.6, 59.5)
52.5
(43.7, 58.4)
Height, cm 155
(145 164)
[1]
157
(149, 165)
[0]
aPCDAI, N = 71
Score = 0 20
(57)
16
(44)
Score = 5 9
(26)
16
(44)
Score = 10 6
(17)
4
(11)
PUCAI, N = 15
Score = 0 4
(50)
7
(78)
Score = 5 4
(50)
2
(22)
Values shown are n (%) ormedian (IQR)with number ofmissing values [m]where appro-
priate. IQR= interquartile range; BMI= bodymass index; aPCDAI= abbreviated Crohn's
disease activity index; PUCAI = paediatric ulcerative colitis activity index.
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bust our estimates and inferences are to the missing data. Baseline QOL
scores, age at randomisation, gender, disease type and consultation
group were used in the imputation model. The number of imputed
datasets was set to be greater than the percentage of missing data in
both groups (White et al., 2011).
Efﬁcacy of treatment was evaluated by a complier-adjusted causal
effect analysis using an instrumental variable approach (Nagelkerke
et al., 2000; Dunn and Bentall, 2007) with minimal participation/non-
participation in the allocated consultation type by 12 month follow-up
included as a mediator, and allocated consultation type as an instru-
mental variable. A treatment by disease-type interaction was also
modelled to assess differential effects in the Crohn's disease and ulcera-
tive colitis/indeterminate colitis subgroups. This trial is registered with
ClinicalTrials.gov, number NCT02319798.
2.6. Economic Evaluation
The economic evaluation compared costs incurred in each group
from the point of randomisation to the end of the 2-year follow-up pe-
riod from the perspective of the NHS.We estimated the costs to provide
telephone consultations and face-to-face consultations by combining
the time needed to do the consultations and matched them with the
unit cost of health and social care (Curtis, 2010). The costs used included
medical consultant level wages/salary (since all the consultations in this
study were conducted by consultants), national insurance, overheads,
training, and capital overheads. We originally also intended to collect
data on costs from the perspective of the patient/parents using a patient
diary, which was distributed to patients at the start of randomisation.
Unfortunately, the completion rate of the diaries was very poor and
we did not obtain adequate data to allow the assessment of these costs.
2.7. Role of the Funding Source
This study was funded by the Research for Patient Beneﬁt Pro-
gramme, UK National Institute for Health Research. The funding source
had no role in the study design, data collection, data analysis, data inter-
pretation, or writing of the report. The corresponding author had full
access to all the data in the study and had ﬁnal responsibility for the
decision to submit for publication.
3. Results
Recruitment ran between July 12, 2010 and June 30, 2011, with
follow-up completed on June 30, 2013. Fig. 1 shows the reasons for in-
eligibility and the ﬂow of participants through the trial. Of 287 patients
assessed for eligibility, 86 were randomly assigned: 44 to the telephone
group and 42 to the face-to-face group. Characteristics at enrolment
were reasonably well balanced between the two groups (Table 1).
At baseline and 12months, 98% and 78%of participants had returned
a QOL questionnaire and were included in the primary analysis (98%
and 88% for the face-to-face and 97% and 68% for the telephone consul-
tation groups respectively). A total of 13 (15%) participants had with-
drawn from the study by the completion of the trial, 8 (19%) from the
face-to-face group and 5 (11%) from the telephone group. Any available
follow-up data for withdrawn patients e.g. a returned questionnaire
was used in analysis as per the ITT principle. One participant allocated
to telephone consultation group reverted to face-to-face consultations.
In the face-to-face consultation group 40 (95%) participants had at
least one consultation, as allocated before the 12 month follow-up.
This ﬁgure was 36 (82%) for the telephone consultation group. For the
period participants remained in the study, the median (IQR) number
of consultations scheduled by the hospital for each patient which
were not then cancelled by the hospital was 5 (3 to 6) for the face-to-
face group and 4.5 (3 to 5.3) for the telephone group. The median(IQR) number of consultation attended per patient was 3 (2 to 4) for
the face-to-face group and 4 (3 to 4) for the telephone group.
A summary of all observed outcomes and the treatment effect
estimates is given in Table 2. The median (IQR) of the QOL score in
the face-to-face groupwas 106 (95, 116) and 113 (105, 125) in the tele-
phone group. Fig. 2 illustrates all observed QOL scores at baseline and
12 month follow-up. The speciﬁed ANCOVA model estimated a mean
(95% CI) QOL score of 102.5 (96.5, 108.4) in the face-to-face group and
108.2 (101.6, 114.7) in the telephone group. The treatment effect esti-
mate (95% CI) was then 5.7 (−2.9, 14.3) units on the IMPACT QOL
scale (P = 0.19) in favour of the telephone consultation group.
Sensitivity analysis conﬁrmed that the conclusion of non-inferiority
implied by this conﬁdence interval was robust to a wide range of plau-
sible reasons for missing outcome data. The complier-adjusted analysis
of QOL scores showed similar conclusions when there was at least min-
imal consultation participation (as deﬁned previously); the efﬁcacy-
based treatment effect estimate (95% CI) was 4.8 (−4.1 to 13.6) points;
p = 0.285. There was no evidence that the treatment effect differed
between Crohn's disease and ulcerative colitis/indeterminate colitis
subgroups (p = 0.15).
For the anthropometric scores, therewas no evidence of a difference
between telephone consultation and face-to-face consultation. Disease
relapses deﬁned by a single or multiple PUCAI or aPCDAI scores greater
than 15 over the 24month follow-up periodwere so rare (4 [10%] in the
face-to-face arm and 1 [2%] in the telephone arm) as to prevent amulti-
factorial analysis, so Fisher's exact test was used. There were no statisti-
cally signiﬁcant differences between the control and intervention arm
Table 2
Summary of outcomes, number of participants or median values given for summary.
Outcome Control “face-to-face” Missing,
n (%)
Intervention
“telephone”
Missing,
n (%)
Adjusted treatment effect
(95% CI)
P
IMPACT QOL score at 12 months 106
(95, 116)
6
(14)
113
(105, 125)
13
(30)
5.7
(−2.9, 14.3)
0.19
Disease relapses over 24 months 4
(10)
1
(2)
0.20
BMI z-score at 12 months 0.020
(−0.85, 1.02)
11
(26)
0.329
(−0.63, 0.57)
19
(44)
0.34
(−0.02, 0.69)
0.06
Weight z-score at 12 months 0.39
(−0.86, 0.96)
11
(26)
0.548
(−0.35, 1.04)
19
(44)
0.08
(−0.22, 0.37)
0.59
Height z-score at 12 months −0.13
(−0.85, 1.07)
11
(26)
0.21
(−0.53, 1.50)
19
(44)
−0.04
(−0.32, 0.24)
0.79
CSQ-child (modiﬁed) by 24 months 46
(44, 51)
2
(5)
48
(45, 51)
8
(18)
0.59
(−2.05, 3.24)
0.65
CSQ-parent (modiﬁed) by 24 months 48
(44, 52)
2
(5)
48
(45, 51)
8
(18)
0.44
(−2.01, 2.89)
0.72
Proportion of out-patient consultations attended
over 24 months, %
71
(50, 80)
0
(0)
67
(50, 75)
1
(2)
1.06
(0.784, 1.43)
0.71
Duration of consultations over 24 months, mins 14.3
(11.6, 17.0)
1
(2)
9.8
(8, 12.3)
3
(7)
4.3
(2.8, 5.7)
b0.001
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participating children or their parents.
There was a statistically signiﬁcant lower mean consultation time
for telephone consultations across all available follow-up compared
to face-to-face consultation. Mean consultation times were 9.8 min
(IQR 8 to 12.3) for telephone consultation, and 14.3 min (11.6 to 17.0)
for face-to-face consultation with an estimated reduction (95% CI) of
4.3 (2.8 to 5.7) min in consultation times (p b 0.001). One participant
in each consultation group had one or more hospital admissions due
to IBD. There was no evidence for a difference in the proportion of
out-patient appointments attended between trial arms by binomial lo-
gistic regression.
Estimates of NHS costs for the intervention (including staff costs and
telephone costs) showed that telephone consultation had a mean cost
of UK£35.41 per patient consultation compared with £51.12 for face–
face consultation, difference £15.71 (95% CI 11.8–19.6; P b 0.001).
No adverse events were noted for either intervention. One patient in
the telephone group died during follow-up but the cause of death was
neither related to the disease nor the intervention.
4. Discussion
To the best of our knowledge, this is the ﬁrst randomised controlled
trial that has formally investigated the role of telephone consultation
in paediatric IBD. Telephone consultation was shown not to be inferior
to face-to-face consultation with regard to QOL scores, and did reduce
consultation time and NHS costs. Whilst the study was, a priori, a
superiority trial, the design, analysis, and results of the trial do not
preclude post-hoc conclusions about the non-inferiority of telephone
consultation.
Non-trivial proportions of missing data in some of the secondary
outcomes may present a considerable departure from the ITT princi-
ple in our analysis and treatment effect estimates may be subject to
bias.
With an equivalence or non-inferiority conclusion regarding a treat-
ment effect, a potential source of bias towards no difference in the
ﬁndingmay be due to the proportion of participants in the intervention
arm of the study who revert to the control treatment or those partici-
pants in both arms who do not receive any treatment at all. In this
study, these are indicated by the 18% of participants in the telephone
group and 5% of participants in the face-to-face group without any con-
sultations before the 12 month follow-up assessment. These can be
thought of as non-compliers, not engaging in the consultation process.
That these were higher in the telephone group may indicate either areduced need for consultation, or a reduced engagement with the
consultation process. The estimate of the differences between compliers
between groups of 4.8, with a 95% CI of−4.1 to 13.6, was itself not sta-
tistically signiﬁcant in terms of improved efﬁcacy and similar in magni-
tude to that of the main analysis. This also supports our ﬁnding that
participants receiving telephone consultations compared to face-to-
face do not have worse QOL outcomes.
Differences in the number of non-returned QOL questionnaires
at 12 month follow-up (32% telephone group vs. 12% face-to-face
group) mean that the main ﬁndings are subject to non-testable as-
sumptions about missing QOL data from these “non-responders”.
Essentially we assume in our main analysis that the QOL of a given
participant who did not return the survey is no different to that of a
similar participant who did return the survey — termed “ignorable
missing data”. In order to investigate the robustness of our conclusions
to departures from this assumption we performed a sensitivity analysis
under a plausible range of systematic differences between observed
and missing data. These analyses indicate that the treatment effect
estimate of the primary outcome, its inferences and ultimately our con-
clusions are robust to departures from the assumptions of ignorable
missing data.
We analysed the QOL scores as a conditionally normally distributed
continuous outcome and this would seem sensible given the 140 point
scale produced by this instrument. Given the mean values in each arm
reported in this study, there were not likely to be any ‘ﬂoor’ or ‘ceiling’
effects on our estimate. Previous validation studies have assumed a nor-
mal distribution for the QOL score (Otley et al., 2002; Loonen et al.,
2002; Ogden et al., 2011) but there are no previously published detailed
characterisations of this score's distribution in any sample of patients
that we are aware of.
The ﬁndings of this study are consistent with the results of recent
adult IBD studieswhere telemonitoring and teleconsulting using various
information and communication technologies such as a web-based
system, and a home telemanagement system were found to be safe
and feasible (Aguas Peris et al., 2015).
As telephone consultation is not inferior to face-to-face consulta-
tion with regard to QOL scores and actually costs less, by principle of
extended dominance, it can be concluded that telephone consultation
is a cost-effective alternative to face-to-face consultation for the rou-
tine out-patient follow-up of children and adolescents with IBD. In
routine clinical practice, children and adolescents with IBD could be
offered the choice of either telephone consultation or face-to-face
consultation for their routine out-patient follow-up. Those who are
doing well would not have to make unnecessary journeys to hospitals.
Fig. 2. Dot-plot of all observed IMPACT QOL scores at baseline and 12 month follow-up
with medians in each group at each time-point.
1256 A.K. Akobeng et al. / EBioMedicine 2 (2015) 1251–1256By freeing up out-patient clinic spaces, access for patients in relapse and
for newly referred patients could be improved, thus reducing waiting
times for appointments. The ﬁndings of this study could also be applica-
ble to the routine follow-up of children with other chronic diseases.
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